Khaled Nour, MD
Gastroenterology · Newport, TNNPI 1750329413
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.8% of the total across 307 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 52.6% of the total.
Across 307 payments — averaging $14.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Bristol Myers Squibb$560
- Johnson & Johnson$395
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$249
- Pfizer$160
- Ardelyx, Inc.$155
- plus $597 from 14 others
Across 3 payments — averaging $36,783 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$110K
What the payments were for
- Food & beverage$4,36198%
- Education$1002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 190 | $2,345 |
| Bristol Myers Squibb | 32 | $560 |
| Johnson & Johnson | 21 | $395 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $249 |
| Pfizer | 9 | $160 |
| Ardelyx, Inc. | 7 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $147 |
| Gilead | 6 | $116 |
| Intercept Pharmaceuticals, Inc. | 5 | $70 |
| Sanofi | 2 | $63 |
| Nestle Healthcare Nutrition Inc. | 2 | $44 |
| Apollo Endosurgery US Inc | 1 | $27 |
| Ferring Pharmaceuticals Inc. | 2 | $26 |
| QOL Medical, LLC | 1 | $22 |
| Merck | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Shionogi Inc | 1 | $13 |
| Boston Scientific | 1 | $13 |
| Redhill Biopharma Inc. | 1 | $12 |
| Medtronic | 1 | $11 |
How this compares
$4,461 in reported general payments places this provider in the 55th percentile of 336 gastroenterology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 431 | $304,938 |
| CreonLipase/Protease/Amylase | 19 | $48,357 |
| TrulancePlecanatide | 57 | $37,827 |
| XifaxanRifaximin | 12 | $32,440 |
| ZenpepLipase/Protease/Amylase | 11 | $31,125 |
| IbsrelaTenapanor Hcl | 12 | $27,629 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 105 | $17,506 |
| MotegrityPrucalopride Succinate | 27 | $16,019 |
| Dexlansoprazole DrDexlansoprazole | 57 | $10,561 |
| Sucralfate | 49 | $8,272 |
| Pantoprazole Sodium | 898 | $8,010 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 214 | $3,447 |
| Dicyclomine Hcl | 219 | $2,473 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 109 | $2,146 |
| Nortriptyline Hcl | 294 | $1,869 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon | $2,345 | $353,294450 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Xifaxan | $249 | $70,26669 claims |
| Ardelyx, Inc.Ibsrela | $155 | $27,62912 claims |
| Ferring Pharmaceuticals Inc.Clenpiq | $26 | $17,506105 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $147 | $16,01927 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 336 gastroenterology providers in Tennessee.
Other gastroenterology in Newport
- David SchwartzNashville$1.3M
- Ziad YounesGermantown$1M
- Dawn Borromeo BeaulieuNashville$421K
- Satheesh NairMemphis$349K
- Colin HowdenMemphis$291K
- Sara HorstNashville$246K
- Raj NarayaniKnoxville$204K
- Chakradhar ReddyJohnson City$161K
- Leonard BaidooMemphis$152K
- William LylesMaryville$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.